Literature DB >> 29364314

Selective cancer treatment via photodynamic sensitization of hypoxia-responsive drug delivery.

Hua He1, Rongying Zhu, Wei Sun, Kaimin Cai, Yongbing Chen, Lichen Yin.   

Abstract

The precise and selective delivery of chemodrugs into tumors represents a critical requirement for anti-cancer therapy. Intelligent delivery systems that are responsive to a single internal or external stimulus often lack sufficient cancer selectivity, which compromises the drug efficacy and induces undesired side effects. To overcome this dilemma, we herein report a cancer-targeting vehicle which allows highly cancer-selective drug release in response to cascaded external (light) and internal (hypoxia) dual triggers. In particular, doxorubicin (DOX)-loaded, hypoxia-dissociable nanoparticles (NPs) were prepared from self-assembled polyethylenimine-nitroimidazole (PEI-NI) micelles that were further co-assembled with hyaluronic acid-Ce6 (HC). Upon accumulation in tumor cells, tumor site-specific light irradiation (660 nm, 10 mW cm-2) generated high levels of reactive oxygen species (ROS) and greatly enhanced the hypoxic levels to induce NP dissociation and accordingly DOX release. A synergistic anti-cancer efficacy between DOX-mediated chemotherapy and Ce6-mediated photodynamic therapy (PDT) was thus achieved, resulting in reduced side effects to normal tissues/cells. This study therefore provides an effective method to control the cancer-specific drug delivery by responding to cascaded multiple triggers, and it renders promising applications for the programmed combination of chemotherapy and PDT toward cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29364314     DOI: 10.1039/c7nr07677k

Source DB:  PubMed          Journal:  Nanoscale        ISSN: 2040-3364            Impact factor:   7.790


  14 in total

Review 1.  Fighting Hypoxia to Improve PDT.

Authors:  Ludivine Larue; Bauyrzhan Myrzakhmetov; Amina Ben-Mihoub; Albert Moussaron; Noémie Thomas; Philippe Arnoux; Francis Baros; Régis Vanderesse; Samir Acherar; Céline Frochot
Journal:  Pharmaceuticals (Basel)       Date:  2019-10-30

2.  Cascade Drug-Release Strategy for Enhanced Anticancer Therapy.

Authors:  Xu Zhang; Sheng Wang; Guohui Cheng; Peng Yu; Jin Chang; Xiaoyuan Chen
Journal:  Matter       Date:  2021-01-06

Review 3.  Tumor microenvironment-responsive nanoparticles for cancer theragnostic applications.

Authors:  Saji Uthaman; Kang Moo Huh; In-Kyu Park
Journal:  Biomater Res       Date:  2018-08-23

4.  Liposomal Dendritic Cell Vaccine in Breast Cancer Immunotherapy.

Authors:  Hong Pan; Hongyan Shi; Peng Fu; Pengfei Shi; Jianyuan Yang
Journal:  ACS Omega       Date:  2021-01-25

Review 5.  Harnessing Endogenous Stimuli for Responsive Materials in Theranostics.

Authors:  Alexander B Cook; Paolo Decuzzi
Journal:  ACS Nano       Date:  2021-02-08       Impact factor: 15.881

Review 6.  Application of Nano-Drug Delivery System Based on Cascade Technology in Cancer Treatment.

Authors:  Ying Sun; Xiaoli Ma; Hao Hu
Journal:  Int J Mol Sci       Date:  2021-05-27       Impact factor: 5.923

Review 7.  Stimuli-Responsive Polymeric Nanoplatforms for Cancer Therapy.

Authors:  Di Chang; Yuanyuan Ma; Xiaoxuan Xu; Jinbing Xie; Shenghong Ju
Journal:  Front Bioeng Biotechnol       Date:  2021-06-25

8.  MFP-FePt-GO Nanocomposites Promote Radiosensitivity of Non-Small Cell Lung Cancer Via Activating Mitochondrial-Mediated Apoptosis and Impairing DNA Damage Repair.

Authors:  Shan Peng; Yingming Sun; Yuan Luo; Shijing Ma; Wenjie Sun; Guiliang Tang; Shuying Li; Nannan Zhang; Jiangbo Ren; Yu Xiao; Xuefeng Liu; Junhong Zhang; Yan Gong; Conghua Xie
Journal:  Int J Biol Sci       Date:  2020-05-18       Impact factor: 6.580

Review 9.  Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics.

Authors:  Peng Mi
Journal:  Theranostics       Date:  2020-03-15       Impact factor: 11.556

10.  Nanostructured Lipid Carriers Delivering Sorafenib to Enhance Immunotherapy Induced by Doxorubicin for Effective Esophagus Cancer Therapy.

Authors:  Jia-Yang Wang; Ya-Qi Song; Jing Peng; Hong-Lei Luo
Journal:  ACS Omega       Date:  2020-09-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.